2023 Journal Article The TRIM31-paradox: an unexpected benefit for leukemia stem cellsStraube, Jasmin and Lane, Steven W. (2023). The TRIM31-paradox: an unexpected benefit for leukemia stem cells. Haematologica, 108 (8), 1982-1983. doi: 10.3324/haematol.2022.282622 |
2023 Journal Article Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationIland, Harry J, Russell, Nigel H., Dillon, Richard, Schuh, Andre C., Tedjaseputra, Aditya, Wei, Andrew H., Khwaja, Asim, Knapper, Steven, Lane, Steven W, Reynolds, John, McMullin, Mary Frances Frances, Martin, Annalise Maria, Tan, Peter, Taussig, David Christopher C, Wong, Anny, Taper, John M, Fraga, Christina, Kelly, Richard, Tawana, Kiran, Mehta, Priyanka, Mina, Alain, Altman, Jessica K., Mølle, Ingolf, Tauro, Sudhir and Tholouli, Eleni (2023). Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation. Blood Advances, 7 (11), 2580-2585. doi: 10.1182/bloodadvances.2022007126 |
2023 Journal Article Shelter from the cytokine storm in myelofibrosisLane, Steven W. (2023). Shelter from the cytokine storm in myelofibrosis. Blood, 141 (20), 2415-2416. doi: 10.1182/blood.2023019779 |
2023 Journal Article Culturally adapted motivational interviewing with cognitive behavior therapy and mindfulness-based relapse prevention for substance use disorder in Pakistan (CAMAIB): protocol for a feasibility factorial randomised controlled trialAsif, Muqaddas, Khoso, Ameer B. B., Husain, M. Ali, Shahzad, Salman, Van Hout, Marie-Claire, Rafiq, Noor-ul-Zaman, Lane, Steven, Chaudhry, Imran Bashir and Husain, Nusrat (2023). Culturally adapted motivational interviewing with cognitive behavior therapy and mindfulness-based relapse prevention for substance use disorder in Pakistan (CAMAIB): protocol for a feasibility factorial randomised controlled trial. Pilot and Feasibility Studies, 9 (1) 67, 111. doi: 10.1186/s40814-023-01296-0 |
2023 Journal Article Oncogenic drivers dictate immune control of acute myeloid leukemiaAustin, Rebecca J., Straube, Jasmin, Halder, Rohit, Janardhanan, Yashaswini, Bruedigam, Claudia, Witkowski, Matthew, Cooper, Leanne, Porter, Amy, Braun, Matthias, Souza-Fonseca-Guimaraes, Fernando, Minnie, Simone A., Cooper, Emily, Jacquelin, Sebastien, Song, Axia, Bald, Tobias, Nakamura, Kyohei, Hill, Geoffrey R., Aifantis, Iannis, Lane, Steven W. and Bywater, Megan J. (2023). Oncogenic drivers dictate immune control of acute myeloid leukemia. Nature Communications, 14 (1) 2155, 1-14. doi: 10.1038/s41467-023-37592-9 |
2023 Journal Article Could an artificial intelligence approach to prior authorization be more human?Lenert, Leslie A., Lane, Steven and Wehbe, Ramsey (2023). Could an artificial intelligence approach to prior authorization be more human?. Journal of the American Medical Informatics Association. doi: 10.1093/jamia/ocad016 |
2023 Journal Article Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemiaStraube, Jasmin, Eifert, Theresa, Vu, Therese, Janardhanan, Yashaswini, Haldar, Rohit, von Eyss, Björn, Cooper, Leanne, Bruedigam, Claudia, Ling, Victoria Y., Cooper, Emily, Patch, Ann-Marie, Bullinger, Lars, Schnoeder, Tina M., Bywater, Megan, Heidel, Florian H. and Lane, Steven W. (2023). Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia. Leukemia, 37 (4), 741-750. doi: 10.1038/s41375-023-01832-0 |
2023 Journal Article Real world molecular characterisation and clonal evolution of acute myeloid leukaemia reveals therapeutic opportunities and challengesNelles, Ricky, Seymour, Louise, Richmond, Joshua and Lane, Steven (2023). Real world molecular characterisation and clonal evolution of acute myeloid leukaemia reveals therapeutic opportunities and challenges. Pathology, 55 (1), 64-70. doi: 10.1016/j.pathol.2022.07.019 |
2023 Journal Article t(15;17) in acute promyelocytic leukemiaLing, Victoria Y. and Lane, Steven W. (2023). t(15;17) in acute promyelocytic leukemia. Haematologica, 108 (2), 295-296. doi: 10.3324/haematol.2022.282577 |
2023 Conference Publication Immunoproteasome Function Maintains Oncogenic Gene Expression In Kmt2a-complex Driven LeukemiaHeidel, Florian, Tubio-Santamaria, Nuria, Jayavelu, Ashok Kumar, Schnoeder, Tina, Eifert, Theresa, Hsu, Chen-Jen, Perner, Florian, Zhang, Qirui, Wenge, Daniela, Hansen, Fynn, Jyotsana, Nidhi, Lane, Steven, von Eyss, Björn, Deshpande, Aniruddha, Kühn, Michael, Schwaller, Jürg, Ebstein, Frederic, Krüger, Elke, Hochhaus, Andreas, Heuser, Michael, Ori, alessandro, Mann, Matthias and Armstrong, Scott (2023). Immunoproteasome Function Maintains Oncogenic Gene Expression In Kmt2a-complex Driven Leukemia. 2023 Annual Scientific Meeting of the ISEH – International Society for Experimental Hematology, New York, NY United States, 17-20 August 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/j.exphem.2023.06.049 |
2023 Journal Article Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemiaLing, Victoria Y., Straube, Jasmin, Godfrey, William, Haldar, Rohit, Janardhanan, Yashaswini, Cooper, Leanne, Bruedigam, Claudia, Cooper, Emily, Tavakoli Shirazi, Paniz, Jacquelin, Sebastien, Tey, Siok-Keen, Baell, Jonathan, Huang, Fei, Jin, Jianwen, Zhao, Yichao, Bullinger, Lars, Bywater, Megan J. and Lane, Steven W. (2023). Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia. Leukemia, 37 (1), 143-153. doi: 10.1038/s41375-022-01755-2 |
2022 Conference Publication Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CMLYeung, David T., Shanmuganathan, Naranie, Reynolds, John, Branford, Susan, Walia, Mannu, Yong, Agnes S.M., Shortt, Jake, Burbury, Kate, Viiala, Nicholas, Cunningham, Ilona, Ross, David M., Harrup, Rosemary, Wright, Matthew, Forsyth, Cecily, D'Souza, Alwyn Bernard, Filshie, Robin J., Browett, Peter J., Lane, Steven W., Grove, Carolyn, Grigg, Andrew and Hughes, Timothy (2022). Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-157244 |
2022 Conference Publication Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid LeukemiaBruedigam, Claudia, Porter, Amy H., Song, Axia, Vroeg in de Wei, Gerjanne, Stoll, Thomas, Straube, Jasmin, Cooper, Leanne T., Cheng, Guidan, Kahl, Vivian F.S., Sobinoff, Alexander, Ling, Victoria Y., Jebaraj, Billy Michael Chelliah, Bray, Laura J., Bullinger, Lars, Heidel, Florian H., Kennedy, Glen A., Hill, Michelle M., Pickett, Hilda, Abdel-Wahab, Omar, Hartel, Gunter and Lane, Steven W. (2022). Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-168166 |
2022 Journal Article Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunityMinnie, Simone A., Waltner, Olivia G., Ensbey, Kathleen S., Nemychenkov, Nicole S., Schmidt, Christine R., Bhise, Shruti S., Legg, Samuel R. W., Campoy, Gabriela, Samson, Luke D., Kuns, Rachel D., Zhou, Ting, Huck, John D., Vuckovic, Slavica, Zamora, Danniel, Yeh, Albert, Spencer, Andrew, Koyama, Motoko, Markey, Kate A., Lane, Steven W., Boeckh, Michael, Ring, Aaron M., Furlan, Scott N. and Hill, Geoffrey R. (2022). Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity. Science Immunology, 7 (76) eabo3420, 1-18. doi: 10.1126/sciimmunol.abo3420 |
2022 Journal Article Paving the way to improve therapy for Myeloproliferative NeoplasmsBywater, Megan and Lane, Steven W. (2022). Paving the way to improve therapy for Myeloproliferative Neoplasms. Nature Communications, 13 (1) 5025. doi: 10.1038/s41467-022-32694-2 |
2022 Journal Article Epigenetic activation of Plasmacytoid DCs drives IFNAR-dependent therapeutic differentiation of AMLSalmon, Jessica M., Todorovski, Izabela, Stanley, Kym L., Bruedigam, Claudia, Kearney, Conor J., Martelotto, Luciano G., Rossello, Fernando, Semple, Timothy, Arnau, Gisela Mir, Zethoven, Magnus, Bots, Michael, Bjelosevic, Stefan, Cluse, Leonie A., Fraser, Peter J., Litalien, Veronique, Vidacs, Eva, McArthur, Kate, Matthews, Antony Y., Gressier, Elise, De Weerd, Nicole A., Lichte, Jens, Kelly, Madison J., Hogg, Simon J., Hertzog, Paul J., Kats, Lev M., Vervoort, Stephin J., De Carvalho, Daniel D., Scheu, Stefanie, Bedoui, Sammy ... Johnstone, Ricky W. (2022). Epigenetic activation of Plasmacytoid DCs drives IFNAR-dependent therapeutic differentiation of AML. Cancer Discovery, 12 (6), 1560-1579. doi: 10.1158/2159-8290.CD-20-1145 |
2022 Journal Article Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statementEnjeti, Anoop K., Agarwal, Rishu, Blombery, Piers, Chee, Lynette, Chua, Chong Chyn, Grigg, Andrew, Hamad, Nada, Iland, Harry, Lane, Steven, Perkins, Andrew, Singhal, Deepak, Tate, Courtney, Tiong, Ing Soo and Ross, David M. (2022). Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. Pathology, 54 (4), 389-398. doi: 10.1016/j.pathol.2022.03.002 |
2022 Journal Article Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantationTey, Siok-Keen and Lane, Steven W (2022). Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation. Blood Advances, 6 (5), 1619-1622. doi: 10.1182/bloodadvances.2021004829 |
2022 Journal Article PLCG1 is required for AML1-ETO leukemia stem cell self-renewalSchnoeder, Tina M., Schwarzer, Adrian, Jayavelu, Ashok Kumar, Hsu, Chen-Jen, Kirkpatrick, Joanna, Döhner, Konstanze, Perner, Florian, Eifert, Theresa, Huber, Nicolas, Arreba-Tutusaus, Patricia, Dolnik, Anna, Assi, Salam A, Nafria, Monica, Jiang, Lu, Dai, Yu-Ting, Chen, Zhu, Chen, Sai-Juan, Kellaway, Sophie G., Ptasinska, Anetta, Ng, Elizabeth S., Stanley, Edouard G., Elefanty, Andrew G., Buschbeck, Marcus, Bierhoff, Holger, Brodt, Steffen, Matziolis, Georg, Fischer, Klaus-Dieter, Hochhaus, Andreas, Chen, Chun-Wei ... Heidel, Florian (2022). PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood, 139 (7), 1080-1097. doi: 10.1182/blood.2021012778 |
2021 Conference Publication A Phase- Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT<sub>3</sub>-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study)Kipp, David, Loo, Sun, Perkins, Andrew Charles, Lane, Steven W., Blyth, Emily, Ejeti, Anoop Kumar, Bajel, Ashish, Reynolds, John and Wei, Andrew H. (2021). A Phase- Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood-2021-154247 |